Regulating Sensitivity to Cancer Therapy with Engineered Transcription Factors

描述（由申请人提供）：细胞凋亡途径的失调导致对旨在诱导细胞死亡的癌症治疗剂的耐药性。虽然在理解细胞凋亡方面已经取得了许多进展，但涉及对特定细胞凋亡刺激的抗性或敏感性的分子特征尚不清楚。基因的鉴定，影响细胞对基于肿瘤的治疗反应将显着推进癌细胞生物学领域和有效的抗癌策略的合理设计。特别是，这项研究将集中在肿瘤坏死因子相关的凋亡诱导配体（TRAIL），它选择性地刺激癌细胞而不是正常细胞的细胞死亡。然而，正常细胞和特定转化细胞获得对TRAIL的抗性的机制仍然知之甚少。我们的长期目标是确定新的基因靶点，以设计有效的抗癌治疗方法。这项工作的基本原理是，工程转录因子库是一种独特而强大的工具，可用于识别参与调节致敏性或对肿瘤诱导癌症疗法的抗性的基因。该提案的总体目标是鉴定用于改进的基于糖尿病的疗法的靶向基因。我们的假设是，工程转录因子（ETFs）的文库中确定的基因将调节敏感性和阻力TRAIL介导的凋亡。该目标将通过检验我们的假设来实现，具有以下具体目标：（1）鉴定调节对TRAIL诱导的细胞凋亡的敏感性的基因;（2）鉴定调节TRAIL介导的肿瘤发展抑制的基因;（3）评价TRAIL受体和诱饵受体表达在调节TRAIL敏感性中的作用。最近由申办者的实验室开发了ETF文库，以激活或抑制与复杂细胞表型相关的基因表达。我们将使用这个工具来识别基因，赋予抵抗力或增强敏感性的癌细胞和正常细胞中的肿瘤坏死因子相关凋亡诱导配体使用一个基于肿瘤坏死因子的选择策略。此外，我们将使用这些库与人类异种移植肿瘤模型相结合，以确定在体内调节TRAIL活性的基因。最后，ETFs将用于调节TRAIL受体的表达，并阐明这些受体在选择性TRAIL活性中的作用。在这项工作中确定的基因将作为设计癌症疗法的基础，这些疗法可以有效地消除癌细胞，对正常组织的影响最小。这些治疗将通过在治疗期间最大化非癌性器官的健康，限制重复治疗的需要，并降低无效癌症治疗导致的死亡率来显著提高癌症患者的生活质量。

DESCRIPTION (provided by applicant): Deregulation of the apoptotic pathway is responsible for resistance to cancer therapeutics designed to induce cell death. Although there have been many advances in understanding apoptosis, the molecular characteristics involved in resistance or sensitivity to specific apoptotic stimuli are unclear. The identification of genes, which influence the cellular response to apoptosis-based therapeutics will significantly advance the field of cancer cell biology and the rational design of effective anti-cancer strategies. In particular, this research will focus on the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which selectively stimulates cell death in cancer cells but not normal cells. However the mechanisms by which normal cells and particular transformed cells obtain resistance to TRAIL remain poorly understood. Our long-term goal is to identify novel gene targets for the design of effective anti-cancer therapeutics. The rationale for the proposed work is that libraries of engineered transcription factors are a unique and powerful tool for identifying genes involved in regulating sensitization or resistance to apoptosis-inducing cancer therapies. The overall objective of this proposal is to identify genes to be targeted for improved apoptosis-based therapeutics. Our hypothesis is that genes identified by libraries of engineered transcription factors (ETFs) will modulate sensitivity and resistance to TRAIL-mediated apoptosis. The objective will be accomplished by testing our hypothesis with the following specific aims: (1) Identify genes that regulate sensitivity to TRAIL-induced apoptosis; (2) Identify genes that regulate TRAIL-mediated suppression of tumor development; (3) Evaluate the role of TRAIL receptor and decoy receptor expression in regulating TRAIL sensitivity. Libraries of ETFs have been recently developed by the sponsor's laboratory to activate or repress the expression of genes associated with complex cellular phenotypes. We will use this tool to identify genes that confer resistance or enhance sensitivity to TRAIL in cancerous and normal cells using an apoptosis-based selection strategy. Additionally, we will use these libraries in combination with a human xenograft tumor model to identify genes that regulate TRAIL activity in vivo. Finally, ETFs will be used to regulate TRAIL receptor expression and elucidate the role of these receptors in selective TRAIL activity. The genes identified in this work will serve as the basis for designing cancer therapies that effectively eliminate cancer cells with minimal effects on normal tissues. These treatments will dramatically enhance the quality of life of cancer patients by maximizing the health of non-cancerous organs during treatment, limiting the need for repeated treatments, and decreasing mortality resulting from ineffective cancer therapy.